SCHEMBL2285362

SCHEMBL2285362

Cc1cc(O)c(C(=O)C=Cc2cccc(OCCNC(=O)OC(C)(C)C)c2)c(=O)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
ABCG2 Q9UNQ0 2/20 0.40
ABCB1 P08183 1/20 0.40
HDAC3 O15379 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC5 Q9UQL6 2/20 0.39
APP P05067 1/20 0.39
PDK2 Q15119 1/20 0.39
MAOB P27338 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2278989 0.84 ABCG2 (0.47) ABCG2APPMAOBMAOARAB9A
SCHEMBL2278993 0.84 ABCG2 (0.47) ABCG2APPMAOBMAOARAB9A
SCHEMBL2277302 0.83 APP (0.48) ABCG2APPMAOBMAOARAB9A
SCHEMBL2277045 0.83 ABCG2 (0.46) ABCG2APPMAOBMAOASMN1; SMN2
SCHEMBL2284216 0.83 ABCG2 (0.46) ABCG2APPMAOBMAOARAB9A
SCHEMBL2284220 0.83 ABCG2 (0.46) ABCG2APPMAOBMAOARAB9A
SCHEMBL2277049 0.83 ABCG2 (0.46) ABCG2APPMAOBMAOASMN1; SMN2
SCHEMBL2277304 0.83 APP (0.48) ABCG2APPMAOBMAOARAB9A
SCHEMBL2277182 0.81 HDAC3 (0.50) ABCG2ABCB1HDAC3HDAC1HDAC2
SCHEMBL2277187 0.81 HDAC3 (0.50) ABCG2ABCB1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 CA12 2073/4885CA1 2371/4885CA2 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.